Junko Hamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junko Hamamoto has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Yasuda
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
31 shared publications - Kenzo Soejima
Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Japan
30 shared publications - Aki Ookubo
JSR-Keio University Medical and Chemical Innovation Center (JKiC), Tokyo, Japan
23 shared publications - Daisuke Aoki
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
23 shared publications - Hideki Terai
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
23 shared publications - Keiko Ohgino
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Japan
23 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities
RNA splicing dysregulation has emerged as a hallmark of cancer and a promising therapeutic target; however, its full landscape in human solid cancer remains poorly characterized. To address this, we perform alternative splicing analyses using RNA-sequencing data from 751 lung adenocarcinoma samples from our cohort integrated with 519 samples from The Cancer Genome Atlas. Visualization of splicing patterns using t-distributed stochastic neighbor embedding reveals substantial inter-tumor heterogeneity driven by distinct molecular subtypes and histological differentiation. We identify a unique molecular subtype associated with inactivating mutations in CMTR2 , which encodes Cap-specific mRNA (nucleoside-2’-O-)-methyltransferase 2. CMTR2 mutations are observed in 3.8% of cases and are predominantly truncating mutations, which form an isolated cluster within the splicing landscape. Intrinsic and CRISPR-Cas9-engineered CMTR2 mutations disrupt alternative splicing and sensitize cancer cells to sulfonamide-based RNA splicing modulators and immune checkpoint blockade therapy. Retrospective patient data confirm the increased sensitivity of CMTR2 -deficient tumors to immune checkpoint blockade therapy. These findings uncover a previously unrecognized RNA splicing deficiency in human cancers and define a molecular subtype of lung adenocarcinoma driven by RNA splicing dysregulation, suggesting targets for therapeutic intervention in lung cancer.
- 6 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
Open AccessMutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities
RNA splicing dysregulation has emerged as a hallmark of cancer and a promising therapeutic target; however, its full landscape in human solid cancer remains poorly characterized. To address this, we perform alternative splicing analyses using RNA-sequencing data from 751 lung adenocarcinoma samples from our cohort integrated with 519 samples from The Cancer Genome Atlas. Visualization of splicing patterns using t-distributed stochastic neighbor embedding reveals substantial inter-tumor heterogeneity driven by distinct molecular subtypes and histological differentiation. We identify a unique molecular subtype associated with inactivating mutations in CMTR2 , which encodes Cap-specific mRNA (nucleoside-2’-O-)-methyltransferase 2. CMTR2 mutations are observed in 3.8% of cases and are predominantly truncating mutations, which form an isolated cluster within the splicing landscape. Intrinsic and CRISPR-Cas9-engineered CMTR2 mutations disrupt alternative splicing and sensitize cancer cells to sulfonamide-based RNA splicing modulators and immune checkpoint blockade therapy. Retrospective patient data confirm the increased sensitivity of CMTR2 -deficient tumors to immune checkpoint blockade therapy. These findings uncover a previously unrecognized RNA splicing deficiency in human cancers and define a molecular subtype of lung adenocarcinoma driven by RNA splicing dysregulation, suggesting targets for therapeutic intervention in lung cancer.
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Immunoblot analysis of AGR2-knockout 18-015 organoid showing no upregulation of SLFN11
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Immunoblot analysis of AGR2-knockout 18-015 organoid showing no upregulation of SLFN11
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p < 0.0005) (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA). In the molecule, pink indicates actual upregulation, green indicates actual downregulation, orange indicates predicted upregulation, and blue indicates predicted downregulation.
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p < 0.0005) (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA). In the molecule, pink indicates actual upregulation, green indicates actual downregulation, orange indicates predicted upregulation, and blue indicates predicted downregulation.
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Gene expression differences between AGR2-knockout clear cell ovarian cancer organoids and controls (19-042)
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Gene expression differences between AGR2-knockout clear cell ovarian cancer organoids and controls (19-042)
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPITHELIAL_MESENYCHYMAL_TRANSITION, HALLMARK_NOTCH_SIGNALING, HALLMARK_COAGULATION, HALLMARK_PROTEIN_SECRETION, HALLMARK_HYPOXIA). CCC, clear cell ovarian cancer; cont., control; HGSC, high-grade serous ovarian cancer
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPITHELIAL_MESENYCHYMAL_TRANSITION, HALLMARK_NOTCH_SIGNALING, HALLMARK_COAGULATION, HALLMARK_PROTEIN_SECRETION, HALLMARK_HYPOXIA). CCC, clear cell ovarian cancer; cont., control; HGSC, high-grade serous ovarian cancer
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Compounds with inhibition efficiency over 70% (n = 103) in two clear cell ovarian cancer organoids (18-015, 19-042).
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Compounds with inhibition efficiency over 70% (n = 103) in two clear cell ovarian cancer organoids (18-015, 19-042).
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
AGR2-knockout (KO) in AGR2-low clear cell ovarian cancer (CCC) did not suppress cell growth A, Immunoblot analysis confirmed AGR2 KO. B, AGR2 KO did not suppress cell growth in AGR2-low CCC organoid (18-015).
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
AGR2-knockout (KO) in AGR2-low clear cell ovarian cancer (CCC) did not suppress cell growth A, Immunoblot analysis confirmed AGR2 KO. B, AGR2 KO did not suppress cell growth in AGR2-low CCC organoid (18-015).
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Dose–response curve of carboplatin in six clear cell ovarian cancer organoids CCC, clear cell ovarian cancer
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Dose–response curve of carboplatin in six clear cell ovarian cancer organoids CCC, clear cell ovarian cancer
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Cdk1/2/5/9 gene expression differences between dinaciclib-resistant CCC organoids (19-055, 19-076, and 19-079) vs. the dinaciclib-sensitive CCC organoids (180-015, 19-001, 19-010, 19-042, 19-044, 18-148). A log fold change (logFC) greater than 0 was considered to indicate higher gene expression in dinaciclib-resistant samples.
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
Cdk1/2/5/9 gene expression differences between dinaciclib-resistant CCC organoids (19-055, 19-076, and 19-079) vs. the dinaciclib-sensitive CCC organoids (180-015, 19-001, 19-010, 19-042, 19-044, 18-148). A log fold change (logFC) greater than 0 was considered to indicate higher gene expression in dinaciclib-resistant samples.
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
The activation of the UPR in CCC, with a higher level of activation observed following treatment with bortezomib. A, GSEA of the IRE1α pathway, PERK pathway, and ATF6 pathway in CCC, multiple myeloma from TCGA, and normal ovary from the Genotype-Tissue Expression database. B, PCA of ssGSEA using ATF6, IRE1α, and PERK pathways. TCGA-OV, TCGA ovarian cancer; TCGA-PAAD, TCGA pancreatic adenocarcinoma. C, Bright-field image of CCC organoid (19-042) treated with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). D, Immunoblot analysis of UPR markers (IRE1α, XBP1s, PERK, and ATF6) and an apoptosis marker (cleaved caspase-3) following treatment with bortezomib (10 or 50 nmol/L, 24 hours) or dinaciclib (100 or 500 nmol/L, 24 hours). E, TEM images after treatment with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). The arrowhead indicates the ER. Bortezomib treatment at 50 nmol/L significantly induced ER lumen dilatation (P < 0.001), whereas dinaciclib treatment did not. The arrow indicates the abnormal lysosome. Scale bars, 1 μm (top) and 2 μm (bottom). MM, multiple myeloma.
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target
The activation of the UPR in CCC, with a higher level of activation observed following treatment with bortezomib. A, GSEA of the IRE1α pathway, PERK pathway, and ATF6 pathway in CCC, multiple myeloma from TCGA, and normal ovary from the Genotype-Tissue Expression database. B, PCA of ssGSEA using ATF6, IRE1α, and PERK pathways. TCGA-OV, TCGA ovarian cancer; TCGA-PAAD, TCGA pancreatic adenocarcinoma. C, Bright-field image of CCC organoid (19-042) treated with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). D, Immunoblot analysis of UPR markers (IRE1α, XBP1s, PERK, and ATF6) and an apoptosis marker (cleaved caspase-3) following treatment with bortezomib (10 or 50 nmol/L, 24 hours) or dinaciclib (100 or 500 nmol/L, 24 hours). E, TEM images after treatment with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). The arrowhead indicates the ER. Bortezomib treatment at 50 nmol/L significantly induced ER lumen dilatation (P < 0.001), whereas dinaciclib treatment did not. The arrow indicates the abnormal lysosome. Scale bars, 1 μm (top) and 2 μm (bottom). MM, multiple myeloma.